|
The Kerala state branch of the Indian Pharmaceutical Association (IPA) marked a historic milestone on January 21, 2026, with the formal launch of an online ‘Consortium on Innovation and Entrepreneurship in Healthcare’.
This initiative is designed to revolutionize the pharmaceutical landscape by fostering structured partnerships between academic institutions and industrial giants. By focusing on translational research, the consortium aims to accelerate the journey of laboratory discoveries into tangible commercial products that provide significant societal value.
The virtual inauguration was led by Professor Dr B Suresh, Pro-Chancellor of JSS Academy of Higher Education and Research (JSSAHER) in Mysore, who served as the chief guest. During his keynote address, Dr. Suresh emphasized that the rapid pace of global technological advancement necessitates disruptive innovation within the pharmaceutical sector. He urged academic institutions to expand their horizons beyond regional boundaries and focus on converting their research into viable, market-ready solutions.
Reflecting a broad national commitment, the consortium has already secured a powerhouse of intellectual and industrial support. Nearly 40 experts from across India’s regulatory, academic, industry and research sectors have agreed to join the Advisory Board to provide strategic guidance. Besides, 15 prominent pharmaceutical industries and 10 research-led pharmacy colleges have signed on as Founder Partners, establishing a robust foundation for collaborative growth.
Dr John Joseph, secretary, IPA Kerala, welcomed the stakeholders to the session presided over by Dr P Jayasekhar, president of the IPA. During the meeting, Dr Fels Saju detailed the executive structure and specialized working groups of the new pharmaceutical consortium. State support was also highlighted by Anoop Ambika, CEO of the Kerala Startup Mission (KSUM), who noted that the state's rich data resources and advanced clinical protocols make it an ideal hub for healthcare innovation. He pledged the ecosystem's support in mentoring innovators from the initial idea stage all the way to market entry.
Industry leaders contributed strategic insights on how to transform India from a ‘talent factory’ into an active ‘translation engine’ by 2026. Dr. L. Ramaswamy of Sotax Pvt. Ltd. outlined four critical pillars for success, focusing on solvable problems, utilizing predictive approaches to reduce industry failures, creating frictionless IP policies, and embracing interdisciplinary team science.
This sentiment was echoed by J. Jayaseelan, chairman of IDMA south zone, who stressed the importance of incremental innovation involving regulators alongside industry and academia.
A significant portion of the deliberations focused on diversifying research into high-growth sectors such as wellness, herbal, nutraceutical, and cosmetics. Dr. Vijay Bambulkar, formerly of Johnson & Johnson, highlighted the vast entrepreneurial potential in nanoparticle technology and sustainable research within the cosmetic industry. Additionally, the consortium aims to bolster the R&D capabilities of small and medium pharmaceutical enterprises to ensure a more inclusive and resilient healthcare ecosystem.
The integration of traditional knowledge with modern science was also identified as a key priority for the new platform. Dr. J. Hareendran Nair emphasized the necessity of translating Ayurvedic wisdom into modern scientific frameworks through rigorous validation and evidence-based research. Similarly, Dr. Pushpalatha of Himalaya Wellness Company discussed the global impact of integrating traditional herbal formulations with modern scientific approaches.
As the session concluded, Dr.MR. Pradeep delivered the vote of thanks, calling for smoother technology transfer mechanisms to overcome existing regulatory and licensing hurdles.
|